» Articles » PMID: 22120675

MiR-100 Resensitizes Docetaxel-resistant Human Lung Adenocarcinoma Cells (SPC-A1) to Docetaxel by Targeting Plk1

Overview
Journal Cancer Lett
Specialty Oncology
Date 2011 Nov 29
PMID 22120675
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) expression correlates with biological characteristics of both normal cells and cancer cells, but their roles in cancer chemoresistance remain unclear. By microarray analysis, miR-100 was found significantly down-regulated in docetaxel-resistant SPC-A1/DTX cells compared with parental SPC-A1 cells. Ectopic miR-100 expression resensitized SPC-A1/DTX cells to docetaxel by suppression of cell proliferation and induction of cell arrest in G(2)/M phase and apoptosis. Knock-down of Plk1, which was a direct target of miR-100, yielded similar effects as that of ectopic miR-100 expression. The inverse correlation between miR-100 and Plk1 expression was also detected in nude mice SPC-A1/DTX tumor xenografts and clinical lung adenocarcinoma tissues and was proved to be related with the in vivo response to docetaxel. Thus, our results suggested that down-regulation of miR-100 could lead to Plk1 over-expression and eventually to docetaxel chemoresistance of human lung adenocarcinoma.

Citing Articles

miR‑100: A key tumor suppressor regulatory factor in human malignant tumors (Review).

Zhang L, Zhang J, Zhang X, Liu S, Qi C, Gao S Int J Mol Med. 2025; 55(4).

PMID: 40017111 PMC: 11875724. DOI: 10.3892/ijmm.2025.5508.


MiRNAs in Lung Adenocarcinoma: Role, Diagnosis, Prognosis, and Therapy.

Song Y, Kelava L, Kiss I Int J Mol Sci. 2023; 24(17).

PMID: 37686110 PMC: 10487838. DOI: 10.3390/ijms241713302.


miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential.

Yan H, Tang S, Tang S, Zhang J, Guo H, Qin C Front Pharmacol. 2022; 13:949566.

PMID: 36386184 PMC: 9640411. DOI: 10.3389/fphar.2022.949566.


Sustained Supratherapeutic Paclitaxel Delivery Enhances Irreversible Sarcoma Cell Death.

Blessing W, Digesu C, Liu R, Mahvi D, Tal-Mason A, Kumar A Mol Cancer Ther. 2022; 21(11):1663-1673.

PMID: 36031342 PMC: 9633561. DOI: 10.1158/1535-7163.MCT-21-0750.


MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.

Marima R, Francies F, Hull R, Molefi T, Oyomno M, Khanyile R Biomedicines. 2021; 9(12).

PMID: 34944633 PMC: 8698559. DOI: 10.3390/biomedicines9121818.